Introduction
Cancer is one of the leading causes of death globally. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths in 2020. With increasing incidence rates across different types of cancers, there is a growing need for effective treatment options. The oncology drug pipeline holds promise for developing novel therapies to treat various cancers more effectively. This article analyzes the oncology drug pipeline in terms of different types of drugs in development and their therapeutic potential.
Antibody Drug Conjugates
Antibody drug conjugates (ADCs) combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of chemotherapy drugs. By attaching highly potent anti-cancer agents to antibodies that bind to tumor cell antigens, ADCs help deliver chemotherapy selectively to cancer cells while minimizing exposure to normal cells. Currently, there are over 100 ADCs in clinical development targeting various solid and hematologic cancers.
Some key ADCs in late-stage trials include Enhertu (trastuzumab deruxtecan) which is being evaluated in breast and gastric cancers. Besponsa (inotuzumab ozogamicin) and Polivy (polatuzumab vedotin-piiq) are approved for treating acute lymphoblastic leukemia and diffuse large B-cell lymphoma respectively. Mylotarg (gemtuzumab ozogamicin) is approved for acute myeloid leukemia. With their targeted approach, ADCs have the potential to improve response rates and survival outcomes with fewer side effects compared to conventional chemotherapy.
Immunotherapy Drugs
Immunotherapy has emerged as Oncology Drug Pipeline Analysis breakthrough in cancer treatment by activating the body's own immune system to fight cancer. There are several immunotherapies currently in development including checkpoint inhibitors, cancer vaccines, oncolytic viruses, cell therapies among others.
Checkpoint inhibitors that block immune inhibitory pathways like PD-1 and CTLA-4 have already transformed the treatment of various cancers. Drugs such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Tecentriq (atezolizumab) are approved for several cancers. Many other PD-1 and CTLA-4 inhibitors are in late stage testing alone or in combination with other therapies. Other emerging immunotherapies in the pipeline include chimeric antigen receptor (CAR) T-cell therapies for blood cancers. Therapies like Kymriah and Yescarta have gained FDA approval for leukemia and lymphoma respectively based on high response rates in clinical trials.
Targeted Therapies
Targeted therapies impede the growth and spread of cancer by interfering with specific molecular pathways involved in tumor growth and progression. These include small molecule inhibitors targeting oncogenic protein kinases, angiogenesis inhibitors blocking blood supply to tumors, PARP inhibitors for DNA repair deficient cancers and proteasome inhibitors.
Some notable examples in clinical trials include Lotorap (binimetinib), a MEK inhibitor being developed for various cancers with MAPK pathway mutations. Citagrel (avagacestat), a gamma secretase inhibitor is in phase 3 studies for KRAS mutant lung cancer. Mirvetuximab soravtansine, an antibody-drug conjugate targeting folate receptor-alpha is in phase 3 for platinum resistant ovarian cancer. Tibsovo (ivosidenib) gained FDA approval in 2018 for IDH1 mutant leukemia based on high response rates. Many other targeted therapies are in various stages of clinical testing across different cancer types.
Pipeline by Cancer Type
The oncology pipeline includes drugs targeting a wide range of cancer types with unmet needs. Here is a brief overview of select cancer types:
Lung Cancer: It is a leading cause of cancer deaths worldwide. Drugs such as osimertinib (Tagrisso) for EGFR mutations, alectinib (Alecensa) for ALK fusions, pembrolizumab (Keytruda) as a first line therapy are generating positive results. Novel immunotherapies, targeted agents and combinations are in evaluation.
Breast Cancer: Major pipeline drugs include Enhertu for HER2+ metastatic breast cancer, Talzenna (talazoparib) for BRCA mutated cancer, and immunotherapy combinations. Drugs targeting tissue-based subtypes and tumor microenvironment are a focus.
Colorectal Cancer: Drugs such as dostarlimab-gxly (Jemperli) targeting PD-1, FIR/ION combination, and regorafenib-Qawmeg plus combination are in late trials. Novel targets and predictive biomarkers are areas of active research.
Pancreatic Cancer: Despite limited treatment options, seviprotimut-L (vaccine), pexastimogene devacirepvec (oncolytic virus), and drug combinations are raising hope in difficult-to-treat disease. Candidate drugs targeting desmoplasia are in early stages.
Prostate Cancer: Radioisotopes, immune checkpoints inhibitors and targeted therapies are being evaluated in advanced and metastatic settings. Biomarker-dependent treatments hold promise for improving patient selection.
Conclusion
The oncology drug pipeline has expanded tremendously in recent years, driven by advances in understanding cancer biology. Novel targets, platforms and combination strategies are continuously enriching the anti-cancer arsenal. However, only a fraction of candidates ultimately receive approval due to rigorous efficacy and safety standards. With continued research efforts, the goal is to develop more effective and personalized treatment options that can meaningfully improve cancer outcomes across different disease stages and subtypes. The future remains promising as scientific progress continues apace.
Get more insights, On Oncology Drug Pipeline Analysis
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link Key InclusionsA detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders, and others), type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target genes, type of delivery system used, route of administration and special drug designations (if any).A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishment.An analysis of completed, ongoing and planned clinical studies for different types of RNAi molecules.
The trials were analyzed on the basis of various relevant parameters, such as registration year, current status, phase of development, type of RNAi molecule, regional distribution of clinical trials and enrolled patient population.An in-depth analysis of the various patents that have been filed / granted related to RNAi therapeutics, since 2014.
The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.An analysis of the various partnerships pertaining to RNAi therapeutics, which have been established till August 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players.An analysis of the investments made at various stages of development in companies engaged in this domain, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings.An analysis of the key promotional strategies that have been adopted by developers of marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.A review of emerging technology platforms and delivery systems that are being used for targeted therapeutic delivery, featuring detailed profiles of technologies.Detailed profiles of drug candidates that are in the advanced stages of development (phase II/III and above), including information on their current development status, mechanism of action, route of administration, affiliated delivery technology, dosage, recent clinical trial results along with information on their respective developers.An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.
The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:Key therapeutic areasOncological disordersInfectious diseasesGenetic disordersOphthalmic disordersHepatic disordersRespiratory disorders Type of RNAi moleculesiRNAmiRNAshRNAsshRNADNA Route of administrationSubcutaneousIntravenousIntradermalIntratumoralIntravitrealOralIntramuscular Key geographical regionsNorth AmericaEuropeAsia Pacific and the Rest of the World Leading Players The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry.
The report includes detailed transcripts of discussions held with the following expert(s):Amotz Shemi (Chief Executive Officer, Silenseed) To request sample pages, please visit this link Key Questions AnsweredWho are the leading industry players in this market?What are the clinical conditions for which RNAi therapeutics are being developed?Who are the key investors in the RNAi therapeutics market?What kind of commercialization strategies are being adopted by RNAi therapeutics developers?What are the different promotional and reimbursement strategies used for RNAi therapeutics?What are the prevalent R trends related to RNAi therapeutics?What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?What kind of partnership models are used by stakeholders in this industry?Who are the key service providers in this field of therapeutics?How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles: Gene Therapy Market (3rd Edition), 2019-2030Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 Contact UsGaurav Chaudhary+1 (415) 800 [email protected]
The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 14.49 billion by 2026, exhibiting a CAGR of 28.9% during the forecast period.
The rising prevalence of rare diseases around the world will fuel demand for SMA treatment in the forthcoming years, which in turn will aid the growth of the market.
As per the National Policy for the treatment of rare diseases, globally, around 6000 to 8000 rare diseases are estimated to exist with new rare diseases reported on a regular basis.
Furthermore, 80% of all the rare diseases are genetically originated and therefore impact children inexplicably.
Nonetheless, “the growing initiatives by government authorities for pre-diagnosis will impact the spinal muscular atrophy (SMA) treatment market share positively during the forecast period”, predicts our lead analysts at Fortune Business Insights.Market Driver: R Initiatives by Key Players to Spur Sales Opportunities The surge in research and development activities for the improvement of therapies and treatment options by key players will aid the spinal muscular atrophy (SMA) treatment market growth during the forecast period.
Furthermore, the growing initiatives for pre-diagnosis and positive reimbursement policies will boost the spinal muscular atrophy (SMA) treatment market trends in the foreseeable future.
According to a new market research report published by sheer analytics and insights, “The Global Healthcare Regulatory Affairs Market was valued at $56.1 Billion in 2020.
Growing at a high CAGR of more than 10.21% between 2021 and 2031, it is estimated to reach $167.1 Billion by 2031”, as per the latest market research report titled Global Healthcare Regulatory Affairs Market - Industry analysis, size, share, growth, trends, and forecast, 2021-2031.The outsourcing of Healthcare Regulatory Affairs is becoming an essential practice in the biotechnology and pharmaceutical industry.
An increasing geographical expansion activity by the companies that aim for speedy approvals in global markets is expected to drive the adoption of outsourcing models for Healthcare Regulatory Affairs.
Regulatory approval procedures are becoming more time-consuming, and stringent and market players aim to obtain permission for the product in the first attempt to gain higher market shares.
These are some of the key factors that drive market growth during the forecast period.Click full report @ https://www.sheeranalyticsandinsights.com/market-report-research/healthcare-regulatory-affairs-market-21However, in this current pandemic of COVID-19, the motors market affected much.
Apart from that, the rising of the Healthcare Regulatory Affairs sector across the world is anticipated to offer a massive opportunity for market growth in the next forecast period of 2021 to 2031.Geographically, The Healthcare Regulatory Affairs Market is divided into global regions like North America, Europe, Asia- Pacific, Latin America, Middle East, and Africa.
Microbiome Therapeutics Market is expected to value at USD 433.5 million by 2025.
Various initiatives taken by regional governments such as Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are creating awareness among general population regarding advantages of microbiome therapeutics are expected to stimulate market growth over the coming years.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/microbiome-therapeutics-market/request-sample The key driving factors responsible for the growth of Microbiome Therapeutics market : Globally, the microbiome therapeutics market is predicted to grow at higher CAGR in the forecast period, providing numerous opportunities for market players to invest for research and development in the market.
Increasing in the occurrence of gastrointestinal disorders, diabetes, arthritis, and other neurological disorders across the globe are major cause of concern; thus intensifying need for treatment and diagnosis methods for its successful treatment.
Growing incidence related to the diagnostic of the arthritis, and other neurological disorders among adults is expected to further boost growth of microbiome therapeutics industry over the next seven years.
Lack of gut microbiome, which is vital for good health of a person, leads to series of adverse effects on human body.
